Day One Biopharmaceuticals, Inc. is a high-risk pharmaceutical company based in the United States of America. Specializing in ESG-focused clinical-stage biopharmaceutical research, Day One Biopharmaceuticals is committed to developing targeted therapies for genetically defined cancers. Their product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor, with a focus on providing innovative treatments for underserved pediatric cancer patients.